NorthWest Biotherapeutics Inc (NWBO)

[FeMike]

Yep, agreed, and that argument there is pretty much why I say you've got a valid point to consider here. I don't think it's clear cut either way.

Another thing to consider is that at this point, approval is pretty much just a binary to help the stock price out in the short term and limit dilution.

The real 'endgame' for this saga, so to speak, is NICE approval. And that almost certainly isn't happening with artisan. So in terms of real commercialization (reimbursement), Flaskworks is still the bottleneck. Whether we get approved now or later, we still have to wait til Q2/3 Flaskworks validation to submit an application to NICE. But it'd sure be nice to wait on that sitting around $1 and not at $0.20.